SIGY is a medical technology company focused on the treatment of life-threatening inflammatory conditions caused by cytokine storm syndrome. The company has developed a blood purification medical device, and is progressing towards receiving FDA approval to begin human clinical trials. Sigyn is headquartered in San Diego, California, and went public in October 2020.
FRC Analyst's Reports
|Sigyn Therapeutics Inc. (OTC PINK: SIGY) – A Potential Solution for The Primary Cause of Death During the COVID-19 Pandemic – Initiating Coverage||
Feb. 25, 2022